Search
Monensin
go.drugbank.com/drugs/DB11430ExperimentalVet approvedMonensin is a polyether isolated from Streptomyces cinnamonensis that presents antibiotic properties. It is widely used in ruminant animal feeds.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsGestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatmen...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAmifampridine
go.drugbank.com/drugs/DB11640ApprovedPatients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnTropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radioth...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cho...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022. Traditionally, the t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnRifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent comp...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalMajor depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was ap...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers